This study is investigating whether a new imaging agent, 18F-fluciclovine, can help doctors see how well large brain metastases (cancers that have spread to the brain) are responding to radiation therapy. You may be able to join if you are an adult (18 years or older) with a confirmed diagnosis of brain metastases, have at least one untreated brain tumor larger than 2 cm, and are planning to receive a specific type of radiation therapy called Stereotactic Radiosurgery (SSRS). The study will measure changes in how well PET/CT and MRI scans detect these tumors, and changes in how much of the 18F-fluciclovine the tumors absorb. The study aims to enroll 20 participants, but its current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 20 participants. The phase of the study is not specified.

What's involved

You will receive a standard dose of 18F-fluciclovine intravenously after fasting for at least four hours. You will then undergo PET/CT brain imaging.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through study completion, which is an average of 1 year, to measure changes in imaging results.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.